Foghorn Non Current Liabilities Total from 2010 to 2025
| FHTX Stock | USD 3.52 0.36 9.28% |
Non Current Liabilities Total | First Reported 2019-12-31 | Previous Quarter 279.8 M | Current Value 262.5 M | Quarterly Volatility 123.1 M |
Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 12.5 M, Interest Income of 12.5 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 10.89, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
Foghorn | Non Current Liabilities Total |
Latest Foghorn Therapeutics' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Foghorn Therapeutics over the last few years. It is Foghorn Therapeutics' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Foghorn Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 131,753,725 | |
| Geometric Mean | 109,486,781 | |
| Coefficient Of Variation | 74.01 | |
| Mean Deviation | 76,872,338 | |
| Median | 78,872,000 | |
| Standard Deviation | 97,508,792 | |
| Sample Variance | 9508T | |
| Range | 306.3M | |
| R-Value | 0.63 | |
| Mean Square Error | 6137.4T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | 12,913,294 | |
| Total Sum of Squares | 142619.5T |
Foghorn Non Current Liabilities Total History
About Foghorn Therapeutics Financial Statements
Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 262.5 M | 200.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.